Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF (2022)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1002/ejhf.2381
- Subjects: INSUFICIÊNCIA CARDÍACA; FIBRILAÇÃO ATRIAL; GLICOSÍDEOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: European journal of heart failure
- ISSN: 1388-9842
- Volume/Número/Paginação/Ano: v. 24, n. 3, p. 513-525, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
- Licença: cc-by-nc
-
ABNT
BUTT, Jawad H. et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European journal of heart failure, v. 24, n. 3, p. 513-525, 2022Tradução . . Disponível em: https://doi.org/10.1002/ejhf.2381. Acesso em: 08 jan. 2026. -
APA
Butt, J. H., Docherty, K. F., Jhund, P. S., Boer, R. A. de, Bohm, M., Desai, A. S., et al. (2022). Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European journal of heart failure, 24( 3), 513-525. doi:10.1002/ejhf.2381 -
NLM
Butt JH, Docherty KF, Jhund PS, Boer RA de, Bohm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF [Internet]. European journal of heart failure. 2022 ; 24( 3): 513-525.[citado 2026 jan. 08 ] Available from: https://doi.org/10.1002/ejhf.2381 -
Vancouver
Butt JH, Docherty KF, Jhund PS, Boer RA de, Bohm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF [Internet]. European journal of heart failure. 2022 ; 24( 3): 513-525.[citado 2026 jan. 08 ] Available from: https://doi.org/10.1002/ejhf.2381 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1002/ejhf.2381 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
